Related Experiment Video
Updated: Feb 2, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic
Sh Hashemzadeh1,2, F Ramezani3, H Rafii-Tabar4
1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Trametinib was endorsed by the FDA in 2013 as a single agent for adult melanoma patients. Trametinib inhibits cell growth and proliferation in multiple tumor xenografts by preventing RAF phosphorylation of MEK and thus restricting accumulation of activated MEK. In this study, the focus of investigation was the mechanism of the interaction between trametinib and MEK1/2 via computational simulation. To specify the best interaction site of inhibitor with MEK1/2 based on the interaction energy ranking, first we performed a docking and then we studied the interactions of the ATP-bound MEK with trametinib, with RAF and the complex of the ATP-bound MEK-trametinib with RAF via molecular dynamic simulations. The results showed that trametinib inactivates the enzyme by bonding to a group of amino acids including Lys97/101, SER218/216, Asp208/212, and Met143/147 in MEK1/2. By bonding to the essential amino acids, trametinib inhibits the activity of the enzyme. All in all, the acquired results can be of great use in designing new inhibitors.
Insights
Trametinib, an FDA-approved melanoma drug, inhibits MEK1/2 by binding to key amino acids. This computational study reveals its precise interaction mechanism, aiding future drug design.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Biology
Background:
- Trametinib is an FDA-endorsed single agent for adult melanoma patients, approved in 2013.
- It functions by inhibiting cell growth and proliferation through the prevention of RAF phosphorylation of MEK, thus limiting activated MEK accumulation.
Purpose of the Study:
- To elucidate the precise mechanism of interaction between trametinib and MEK1/2 using computational simulations.
- To identify the optimal binding site of trametinib on MEK1/2 based on interaction energy.
Main Methods:
- Molecular docking was employed to identify potential interaction sites.
- Molecular dynamic simulations were conducted to study the interactions of ATP-bound MEK with trametinib, with RAF, and the MEK-trametinib-RAF complex.
Main Results:
- Trametinib was found to inactivate MEK1/2 by binding to specific amino acids: Lys97/101, SER218/216, Asp208/212, and Met143/147.
- This binding interaction effectively inhibits the enzymatic activity of MEK1/2.
Conclusions:
- The study provides a detailed computational understanding of trametinib's inhibitory mechanism against MEK1/2.
- These findings can inform the rational design of novel, more effective MEK inhibitors for cancer therapy.
Related Concept Videos
02:00Molecular Models
02:35Molecular Orbital Theory I
02:54Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
03:51Molecular Orbital Theory II
03:07Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy
02:27Predicting Molecular Geometry